Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Current Deferred Revenue: 2022-2025

Historic Current Deferred Revenue for Crinetics Pharmaceuticals (CRNX) over the last 4 years, with Sep 2025 value amounting to $1.6 million.

  • Crinetics Pharmaceuticals' Current Deferred Revenue fell 2.55% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 2.55%. This contributed to the annual value of $2.2 million for FY2024, which is 5.84% up from last year.
  • Crinetics Pharmaceuticals' Current Deferred Revenue amounted to $1.6 million in Q3 2025, which was down 13.76% from $1.9 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' 5-year Current Deferred Revenue high stood at $9.4 million for Q2 2022, and its period low was $1.6 million during Q3 2025.
  • Over the past 3 years, Crinetics Pharmaceuticals' median Current Deferred Revenue value was $2.2 million (recorded in 2025), while the average stood at $4.3 million.
  • Over the last 5 years, Crinetics Pharmaceuticals' Current Deferred Revenue had its largest YoY gain of 185.88% in 2023, and its largest YoY loss of 75.35% in 2023.
  • Quarterly analysis of 4 years shows Crinetics Pharmaceuticals' Current Deferred Revenue stood at $8.3 million in 2022, then slumped by 75.35% to $2.1 million in 2023, then grew by 5.84% to $2.2 million in 2024, then dropped by 2.55% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, $1.9 million for Q2 2025, and $2.2 million during Q1 2025.